U.S. Markets close in 3 hrs 26 mins

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
12.03-0.11 (-0.95%)
As of 12:34PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.15
Open12.12
Bid11.99 x 3200
Ask12.00 x 1100
Day's Range11.81 - 12.13
52 Week Range6.07 - 13.76
Volume2,998,889
Avg. Volume10,042,237
Market Cap13.494B
Beta (5Y Monthly)N/A
PE Ratio (TTM)3,008.75
EPS (TTM)0.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est11.98
  • Teva's Litigation Risks Weigh Against Stabilizing Fundamentals, Analyst Says
    Benzinga

    Teva's Litigation Risks Weigh Against Stabilizing Fundamentals, Analyst Says

    Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported strong quarterly results, prompting an analyst at Barclays to upgrade the stock.The Teva Analyst: Balaji Prasad upgraded Teva from Underweight to Equal-Weight and increased the price target from $10 to $13.The Teva Thesis: Teva reported in-line second-quarter results and reiterated its fiscal year revenue and EPS guidance.Among other things, Ajovy auto-injector saw an improvement in prescription trends and the company has laid long-term growth foundation with the Alvotech biosimilar partnership for five U.S. biosimilar candidates, which represented about $35 billion in innovator sales, the analyst noted.View more earnings on TEVAAmong Prasad's key takeaways are: * Positive prospects for Ajovy in both the U.S. and outside of the U.S. * Austedo sales on track to meet fiscal year 2020 target * Copaxone sales beating expectations * Stable free cash flow * Execution on long-term targetsSee Also: Attention Biotech Investors: Mark Your Calendar For August PDUFA DatesTeva's 2023 financial goals of more than 80% cash conversion and 28% EBIT margins are achievable and sustainable, according to the analyst."While we are cautious on potential legal risks arising from Opioid litigations and Gx Price Fixing cases, we acknowledge the stabilizing fundamentals, improving FCF Generation and reduced leverage profile," Prasat said in the note.TEVA Price Action: Teva shares were sliding 3.6% to $12.20, surrendering some of their 7.3% earnings-induced gains made Wednesday.Latest Ratings for TEVA DateFirmActionFromTo Aug 2020BarclaysUpgradesUnderweightEqual-Weight Aug 2020SVB LeerinkMaintainsMarket Perform Jul 2020Goldman SachsInitiates Coverage OnNeutral View More Analyst Ratings for TEVA View the Latest Analyst Ratings See more from Benzinga * Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing * Why Shares of Denali Therapeutics Are Skyrocketing * The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes
    Zacks

    Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes

    Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.

  • Barrons.com

    Teva CEO Has Doubts About Making Generic-Drug Ingredients in the U.S.

    Kåre Schultz said that simply awarding a large loan doesn’t make the manufacturing of active pharmaceutical ingredients in the U.S. sustainable.